Non-drug industry funded research

doi:10.1136/bmj.39416.559942.BE

Editorial

. 2008 Jan 5;336(7634):1-2.

doi: 10.1136/bmj.39416.559942.BE. Epub 2007 Dec 6.

Non-drug industry funded research

Paolo Bruzzi

PMID: 18063610
PMCID: PMC2174766
DOI: 10.1136/bmj.39416.559942.BE

Editorial

Non-drug industry funded research

Paolo Bruzzi. BMJ. 2008.

. 2008 Jan 5;336(7634):1-2.

doi: 10.1136/bmj.39416.559942.BE. Epub 2007 Dec 6.

Author

Paolo Bruzzi

PMID: 18063610
PMCID: PMC2174766
DOI: 10.1136/bmj.39416.559942.BE

Abstract

Poor access to drugs leaves important clinical questions unanswered

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Comment on

Research, doi: 10.1136/bmj.39401.470648.BE

Cited by

Funding a clinical trial: the perspective of a medicines funder.
Alsop P, Metcalfe S, Evans J. Alsop P, et al. Pharmacoeconomics. 2008;26(10):811-4. doi: 10.2165/00019053-200826100-00002. Pharmacoeconomics. 2008. PMID: 18793029 No abstract available.
The Safety of Long-term Daily Usage of a Proton Pump Inhibitor: A Literature Review.
Abbas MK, Zaidi ARZ, Robert CA, Thiha S, Malik BH. Abbas MK, et al. Cureus. 2019 Sep 4;11(9):e5563. doi: 10.7759/cureus.5563. Cureus. 2019. PMID: 31523592 Free PMC article. Review.
Relation between the global burden of disease and randomized clinical trials conducted in Latin America published in the five leading medical journals.
Perel P, Miranda JJ, Ortiz Z, Casas JP. Perel P, et al. PLoS One. 2008 Feb 27;3(2):e1696. doi: 10.1371/journal.pone.0001696. PLoS One. 2008. PMID: 18301772 Free PMC article.

References

1. Berendt L, Håkansson C, Bach KF, Dalhoff K, Andreasen PB, Petersen LG, et al. Effect of European Clinical Trials Directive on academic drug trials in Denmark: retrospective study of applications to the Danish Medicines Agency 1993-2006. BMJ 2008;336:33. - PMC - PubMed
1. Agenzia Italiana del Farmaco. La sperimentazione clinica dei medicinali in Italia—6° Rapporto Nazionale. 2007. http://oss-sper-clin.agenziafarmaco.it
1. Baum M, Buzdar AU, Cuzik J, Forbes J, Houghton JH, Klijn JG, et al; ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9. Erratum, Lancet 2002;360:1520. - PubMed
1. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, et al; Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92. - PubMed
1. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-802. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Berendt L, Håkansson C, Bach KF, Dalhoff K, Andreasen PB, Petersen LG, et al. Effect of European Clinical Trials Directive on academic drug trials in Denmark: retrospective study of applications to the Danish Medicines Agency 1993-2006. BMJ 2008;336:33. - PMC - PubMed

[2] Berendt L, Håkansson C, Bach KF, Dalhoff K, Andreasen PB, Petersen LG, et al. Effect of European Clinical Trials Directive on academic drug trials in Denmark: retrospective study of applications to the Danish Medicines Agency 1993-2006. BMJ 2008;336:33. - PMC - PubMed

[3] Agenzia Italiana del Farmaco. La sperimentazione clinica dei medicinali in Italia—6° Rapporto Nazionale. 2007. http://oss-sper-clin.agenziafarmaco.it

[4] Agenzia Italiana del Farmaco. La sperimentazione clinica dei medicinali in Italia—6° Rapporto Nazionale. 2007. http://oss-sper-clin.agenziafarmaco.it

[5] Baum M, Buzdar AU, Cuzik J, Forbes J, Houghton JH, Klijn JG, et al; ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9. Erratum, Lancet 2002;360:1520. - PubMed

[6] Baum M, Buzdar AU, Cuzik J, Forbes J, Houghton JH, Klijn JG, et al; ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9. Erratum, Lancet 2002;360:1520. - PubMed

[7] Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, et al; Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92. - PubMed

[8] Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, et al; Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92. - PubMed

[9] Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-802. - PubMed

[10] Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-802. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Non-drug industry funded research

Non-drug industry funded research

Author

Abstract

Conflict of interest statement

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical